KPV Mechanisms and Research Models

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This overview summarizes mechanisms and experimental models used in reviewed studies of KPV (Lys‑Pro‑Val) and related usages, highlighting cellular signaling endpoints, delivery platforms, and model systems represented in the selected literature. Sources include in vitro epithelial and hepatic cell studies, multiple rodent colitis and vitiligo models, and engineered delivery systems such as nanoparticles, hydrogels, liposomes, and an inflammation‑responsive oral prodrug platform (S1, S2, S5, S6, S7, S8, S4, S9, S10).

Research scope and peptide identity

In the reviewed literature, KPV most commonly denotes the tripeptide Lys‑Pro‑Val, described as the C‑terminal sequence of α‑melanocyte‑stimulating hormone and used as an anti‑inflammatory or imaging moiety in multiple cell and animal studies (S5, S2, S6). ^{[S5] [S2] [S6]}

The acronym 'KPV' is used ambiguously in at least one genetic oncology study as an internal genotype label (LSL‑KrasG12D; Tp53fl/fl denoted 'KPV'), which is unrelated to the Lys‑Pro‑Val peptide; this nomenclature ambiguity is present in the reviewed record and should be recognized when aggregating results across sources (S3). ^[S3]

Recent engineering approaches incorporate KPV into delivery platforms (for example, as a payload in an inflammation‑responsive self‑immolative peptide prodrug conjugate) to address gastrointestinal stability and targeted release at inflamed sites (S1). ^[S1]

Mechanisms discussed in cited studies

Multiple cell‑level studies implicate intracellular uptake of KPV (including PepT1‑mediated transport in intestinal epithelial cells) and downstream suppression of inflammatory signaling, notably inhibition of NF‑κB nuclear translocation and modulation of MAPK pathways, resulting in reduced proinflammatory cytokine outputs in epithelial models (S9, S10). ^{[S9] [S10]}

Other mechanistic reports emphasize antioxidant activity: KPV reduced reactive oxygen species (ROS) generation in keratinocyte and hepatocyte models, with downstream effects on MAPK/ERK and p38 signaling, caspase activation, AKT/mTORC1 phosphorylation, and regulation of PPARγ and fatty acid synthase expression in the respective cell systems (S2, S6). ^{[S2] [S6]}

A delivery‑based mechanistic approach used KPV‑modified deformable liposomes to deliver Nlrp3 shRNA for melanocyte‑specific knockdown of NLRP3, linking targeted delivery to modulation of inflammasome activity and downstream pyroptosis in a vitiligo model (S4). ^[S4]

Several studies discuss delivery‑dependent mechanisms: ROS‑responsive release from an inflammation‑triggered prodrug (SIPPC) and electrostatic capture of KPV by negatively charged hydrogels prolong peptide residence at inflamed mucosa, which is associated with enhanced local anti‑inflammatory activity and presumed inhibition of oxidative stress in vivo (S1, S8). ^{[S1] [S8]}

Study models and experimental designs

In vitro models include human HaCaT keratinocytes, HepG2 hepatic epithelial cells, Caco‑2 intestinal epithelial cells, bronchial epithelial cells, and other intestinal epithelial cell lines used to probe uptake, signaling, oxidative stress, cytokine secretion, and imaging behavior (S2, S6, S5, S9, S10). ^{[S2] [S6] [S5] [S9] [S10]}

Rodent in vivo models represented in the reviewed sources include dextran sodium sulfate (DSS)‑induced colitis in mice, TNBS‑induced ulcerative colitis in rats, a colitis mouse model used with an inflammation‑responsive oral prodrug, an acute lung injury mouse model (for off‑target inflammatory accumulation), and a melanoma‑Treg‑induced vitiligo mouse model for melanocyte experiments (S7, S8, S1, S4). ^{[S7] [S8] [S1] [S4]}

Delivery strategies examined include nanoparticle encapsulation with alginate‑chitosan hydrogels, double‑network polyglutamic acid hydrogels for intracolonic retention, KPV‑modified deformable liposomes for melanocyte targeting, a PepT1‑targeted fluorescent probe (DCM‑KPV) for imaging, and self‑immolative peptide prodrug conjugates designed for oral, inflammation‑responsive release (S7, S8, S4, S5, S1). ^{[S7] [S8] [S1] [S5]}

Outcomes measured in the reviewed sources

Keratinocyte outcomes included restored cell viability after particulate matter exposure, reductions in IL‑1β secretion, decreased ROS generation, suppression of ERK and p38 MAPK activation, lowered expression of apoptosis‑related proteins (Bax, Bcl‑2, cleaved caspase‑3), and reduced caspase‑1 activation consistent with decreased pyroptosis (S2). ^[S2]

In HepG2 hepatocyte models, outcomes reported were attenuation of oleic acid–induced lipid accumulation, suppression of fatty acid synthase expression, reductions in ROS, and modulation of AKT/mTORC1 and PPARγ phosphorylation states associated with lipogenic signaling (S6). ^[S6]

In rodent inflammation models, outcomes included enhanced colonic accumulation of a KPV‑based prodrug and improved anti‑inflammatory efficacy in colitis mice, protection against DSS‑induced inflammatory and histologic parameters with KPV‑loaded nanoparticles, improved epithelial barrier recovery and modulation of gut microbiota with hydrogel‑retained KPV, and demonstrated retention and release at inflamed mucosa with various delivery platforms (S1, S7, S8). ^{[S1] [S7] [S8]}

Imaging and diagnostic outcomes included PepT1‑targeted fluorescent accumulation of a DCM‑KPV probe in Caco‑2 cell models and the ability to distinguish chronic versus acute ulcerative colitis tissue in imaging studies by exploiting PepT1‑KPV interactions (S5). ^[S5]

In a vitiligo mouse model, melanocyte‑targeted knockdown of NLRP3 using KPV‑modified liposomes carrying Nlrp3 shRNA was reported to significantly alleviate vitiligo progression, implicating NLRP3 autophagic degradation pathways and inflammasome‑mediated pyroptosis in the disease mechanism (S4). ^[S4]

Cellular signaling outcomes across epithelial models consistently include inhibition of NF‑κB (p65) nuclear translocation and reductions in proinflammatory cytokine production following intracellular KPV exposure or melanocortin receptor agonism (S9, S10). ^{[S9] [S10]}

Reported study-design and protocol details

In HaCaT keratinocyte experiments, KPV was applied at 50 μg/mL and restored cell viability and reduced IL‑1β secretion in PM10‑exposed cells; additional protocol specifics beyond the concentration are not reported in the reviewed excerpt (S2). ^[S2]

In HepG2 cell studies modeling oleic acid–induced steatosis, KPV was used at 100 μg/mL and reduced lipid accumulation and FAS expression without cytotoxicity; further details such as exposure timing and formulation are not reported in the reviewed excerpt (S6). ^[S6]

Nanoparticle delivery work described NP size (approximately 400 nm) and encapsulation of KPV into nanoparticles that were further embedded in an alginate‑chitosan hydrogel; these NP‑KPV constructs reduced inflammatory responses in Caco2‑BBE cells and protected DSS‑treated mice against inflammatory and histologic colitis parameters, although exact peptide doses and administration schedules are not reported in the reviewed excerpt (S7). ^[S7]

A double‑network PMSP hydrogel captured KPV via electrostatic interactions and was administered intracolonically (rectal route) to TNBS‑induced colitis rats; this formulation improved epithelial barrier recovery and modulated gut microbiota, with specific peptide dosing and treatment frequency not reported in the reviewed excerpt (S8). ^[S8]

An inflammation‑triggered self‑immolative peptide prodrug conjugate (SIPPC) platform incorporating KPV was evaluated after oral administration in colitis mice and in a mouse acute lung injury model, reporting a 3.8‑fold greater colonic accumulation of the KPV‑based conjugate compared with free KPV and improved efficacy at a stated '20‑fold lower dose'; the reviewed excerpt does not provide the explicit numerical dosing, frequency, or treatment duration (S1). ^[S1]

A PepT1‑targeted fluorescent probe (DCM‑KPV) was constructed and tested in Caco‑2 cell models with overexpressed PepT1 for imaging uptake and intracellular accumulation; specific probe concentrations and incubation parameters are not reported in the reviewed excerpt (S5). ^[S5]

KPV‑modified deformable liposomes (KPV‑Lipos) carrying Nlrp3 shRNA were used for melanocyte‑specific knockdown in a melanoma‑Treg‑induced vitiligo mouse model and reportedly alleviated vitiligo development; the reviewed excerpt does not report dose, route, or treatment schedule details (S4). ^[S4]

Primary literature summaries indicate intracellular KPV uptake via PepT1 in intestinal epithelial models and that oral KPV administration reduced experimental colitis severity in mice, but the reviewed excerpts do not include explicit dosing, frequency, or duration parameters (S9, S10). ^{[S9] [S10]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Evidence is predominantly preclinical (in vitro cell lines and rodent models) with heterogeneous delivery platforms; translation to clinical contexts is not addressed in the reviewed excerpts.
• Several reviewed records omit explicit dosing, frequency, and treatment duration details in the provided excerpts; protocol_rows list 'not reported in the reviewed source' where such details were absent.
• Nomenclature ambiguity: the label 'KPV' is used both for the Lys‑Pro‑Val tripeptide and as a genotype shorthand in at least one oncology study, requiring careful differentiation when synthesizing findings across sources.
• Comparisons across studies are complicated by differing formulations (free peptide, nanoparticle‑encapsulated peptide, hydrogel retention, liposomal shRNA delivery, and prodrug conjugates) that affect bioavailability and local retention; direct efficacy comparisons are not supported by the reviewed excerpts.

Documentation checklist

• Confirm whether 'KPV' references the tripeptide Lys‑Pro‑Val (α‑MSH C‑terminal) or an unrelated genotype label in each source.
• Note the experimental model (cell line, rodent species, or delivery platform) before extrapolating mechanisms.
• When citing protocol details, rely only on values explicitly reported in the reviewed excerpts.
• Flag delivery-format dependencies (free peptide vs. nanoparticle, hydrogel, or prodrug) when summarizing outcomes.
• Record PepT1 expression status in intestinal models if discussing uptake or imaging applications.

Related research supplies

• Alginate and chitosan polysaccharides (hydrogel matrix components) — material documentation
• Gamma‑polyglutamic acid (maleimided and thiolated derivatives) — hydrogel material specification
• Polyethylene glycol (PEG) segments used in self‑immolative prodrug constructs — polymer documentation
• Laboratory labeling and inventory tags for peptide lot tracking and storage records
• Surface‑compatible disinfectants and cleaning documentation for equipment used with peptide formulations

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon → (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon → (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

More KPV research

• KPV Benefits, Uses, and Protocols: What Published Research Reports
• How to Read a Peptide COA Without Getting Fooled
• Peptide Purity vs Identity Testing Explained
• Batch Numbers Explained for Research Supply
• What Does Third-Party Tested Actually Mean?

Sources and references

1. [S1] Cheng J, Wu P, Li C, Han Y, Sun M, Dou Y. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.. Science advances. 2026. PMID: 41533788. DOI: 10.1126/sciadv.aea2989
2. [S2] Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.. Tissue & cell. 2025. PMID: 40073467. DOI: 10.1016/j.tice.2025.102837
3. [S3] Berr AL, Wiese K, Dos Santos G, Koch CM, Anekalla KR, Kidd M. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.. Oncogene. 2023. PMID: 37161053. DOI: 10.1038/s41388-023-02703-9
4. [S4] Zeng K, Zhu Y, Han Z, Xiong S, Zhao Y, Xiao Z. NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.. Cell death and differentiation. 2026. PMID: 40935835. DOI: 10.1038/s41418-025-01578-5
5. [S5] Zeng M, Shao A, Li H, Tang Y, Li Q, Guo Z. Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis.. ACS applied materials & interfaces. 2017. PMID: 28349696. DOI: 10.1021/acsami.7b00936
6. [S6] Lee JY, Lee J, Jung WK, Je JY, Lee SJ. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.. Cytotechnology. 2026. PMID: 42064835. DOI: 10.1007/s10616-026-00967-z
7. [S7] Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.. Gastroenterology. 2010. PMID: 19909746. DOI: 10.1053/j.gastro.2009.11.003
8. [S8] Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.. Acta biomaterialia. 2022. PMID: 35245681. DOI: 10.1016/j.actbio.2022.02.039
9. [S9] Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. primary literature. PMID:
10. [S10] PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. primary literature. PMID:

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.